BioPharma Resources

Drug Trial Radar · NCT03374085

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

200

Actual

Start

Feb 6, 2018

Primary completion

Aug 20, 2025

Study completion Oct 23, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.

Conditions

  • Multiple Myeloma

Interventions

  • CC-92480Drug

    CC-92480

  • DexamethasoneDrug

    Dexamethasone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: From enrollment until at least 28 days after completion of study treatment
  2. Pharmacokinetics- AUCTime frame: Up to approximately 28 days
  3. Pharmacokinetics- CmaxTime frame: Up to approximately 28 days
  4. Pharmacokinetics- TmaxTime frame: Up to approximately 28 days
  5. Pharmacokinetics- t1/2Time frame: Up to approximately 28 days
  6. Pharmacokinetics- CL/FTime frame: Up to approximately 28 days
  7. Pharmacokinetics- Vz/FTime frame: Up to approximately 28 days
  8. Maximum tolerated dose (MTD)Time frame: Up to approximately 28 days
  9. Overall Response Rate (ORR)Time frame: Up to approximately 3 years

Locations

54 sites in 11 countries. Site status is shown where the registry gives one.

  • Local Institution - 103

    Duarte, California

  • Local Institution - 102

    Atlanta, Georgia

  • Local Institution - 105

    Boston, Massachusetts

  • Local Institution - 111

    Buffalo, New York

  • Local Institution - 104

    New York, New York

  • Local Institution - 108

    Spartanburg, South Carolina

  • Local Institution - 101

    Nashville, Tennessee

  • Local Institution - 106

    Houston, Texas

  • Local Institution - 112

    Charlottesville, Virginia

  • Local Institution - 109

    Seattle, Washington

  • Local Institution - 806

    Fitzroy, Australia

  • Local Institution - 804

    Camperdown, New South Wales, Australia

  • Local Institution - 802

    Adelaide, South Australia, Australia

  • Local Institution - 805

    Clayton, Victoria, Australia

  • Local Institution - 803

    Melbourne, Victoria, Australia

  • Local Institution - 904

    Antwerp, Belgium

  • Local Institution - 905

    Ghent, Belgium

  • Local Institution - 901

    Leuven, Belgium

  • Local Institution - 902

    Yvoir, Belgium

  • Local Institution - 201

    Calgary, Alberta, Canada

  • Local Institution - 204

    London, Ontario, Canada

  • Local Institution - 205

    Ottawa, Ontario, Canada

  • Local Institution - 202

    Toronto, Ontario, Canada

  • Local Institution - 206

    Montreal, Quebec, Canada

  • Local Institution - 203

    Québec, Quebec, Canada

  • Local Institution - 503

    Aarhus N, Denmark

  • Local Institution - 501

    Copenhagen, Denmark

  • Local Institution - 502

    Odense, Denmark

  • Local Institution - 601

    Helsinki, Finland

  • Local Institution - 001

    Athens, Greece

  • Local Institution - 705

    Chuo-ku,chiba, Japan

  • Local Institution - 703

    Fukuoka, Japan

  • Local Institution - 704

    Kashiwa, Japan

  • Local Institution - 702

    Kobe, Japan

  • Local Institution - 706

    Kyoto, Japan

  • Local Institution - 701

    Okayama, Japan

  • Local Institution - 152

    Seoul, South Korea

  • Local Institution - 150

    Seoul, South Korea

  • Local Institution - 151

    Seoul, South Korea

  • Local Institution - 403

    Badalona (Barcelona), Spain

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.